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Goals and Objectives 
The goal of the ATSDR series of Case Studies in Environmental Medicine 
(CSEM) is to increase the health professional’s knowledge of hazardous 
substances in the environment and to aid in the evaluation of potentially 
exposed patients. 
After completion of this educational activity, the reader should be able to 
describe the major sources of I-131 in the environment, identify the major 
routes of human exposure, describe the population group most at risk for 
health effects from past exposure to I-131 and why, describe the four 
factors contributing to the internal dose of I-131 contamination, assess a 
patient’s environmental or occupational exposure to I-131, describe the 
diagnostic evaluation of a thyroid nodule in an individual exposed to I­
131, list two important actions to take if an environmental release of I-131 
occurs, discuss indications for prophylactic use of potassium iodine (KI) 
after an I-131 exposure, and list three sources of information one could 
access if there is a release of I-131. 
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Continuing Medical Education (CME) 
The Centers for Disease Control and Prevention (CDC) is accredited by 
the Accreditation Council for Continuing Medical Education (ACCME) to 
provide continuing medical education for physicians. CDC designates this 
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toward the American Medical Association (AMA) Physician’s 
Recognition Award. Each physician should claim only those hours of 
credit that he/she actually spent in the educational activity. 
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This activity for 2.5 contact hours is provided by CDC, which is 
accredited as a provider of continuing education in nursing by the 
American Nurses Credentialing Center’s Commission on Accreditation. 
Continuing Education Units (CEU) 
CDC has been approved as an Authorized Provider of continuing 
education and training programs by the International Association for 
Continuing Education and Training and awards 0.2 continuing education 
units (CEUs). 
Continuing Health Education Specialist (CHES) 
CDC is a designated provider of continuing education contact hours 
(CECH) in health education by the National Commission for Health 
Education Credentialing, Inc. This program is a designated event for the 
CHES to receive 2.0 category 1 contact hours in health education. 
Instructions 
See page 4 
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The questionnaire and posttest must be completed and returned electronically, by fax, or by mail for 
eligibility to receive continuing education credit. 
Instructions for Completing CSEM Online 
1.	 Read this CSEM, Radiation Exposure From Iodine 131; all answers are in the text. 
2.	 Link to the MMWR/ATSDR Continuing Education General Information page (www.cdc.gov/atsdr/ 
index.html). 
3.	 Once you access this page, select the Continuing Education Opportunities link. 
4.	 Once you access the MMWR/ATSDR site online system, select the electronic file and/or register and test 
for a particular ATSDR course. 
a. Under the heading “Register and Take Exam,” click on the test type desired. 
b. If you have registered in this system before, please use the same login and password. This will ensure an 
accurate transcript. 
c. If you have not previously registered in this system, please provide the registration information 
requested. This allows accurate tracking for credit purposes. Please review the CDC Privacy Notice 
(www.cdc.gov/privacy.htm). 
d. Once you have logged in/registered, select the test and take the posttest. 
5.	 Answer the questions presented. To receive continuing education credit, you must answer all of the 
questions. Some questions have more than one answer. Questions with more than one answer will instruct 
you to “indicate all that are true.” 
6.	 Complete the course evaluation and posttest no later than November 23, 2005. 
7.	 You will be able to immediately print your continuing education certificate from your personal transcript. 
Instructions for Completing CSEM on Paper 
1.	 Read this CSEM, Radiation Exposure From Iodine 131; all answers are in the text. 
2.	 Complete the evaluation questionnaire and posttest, including your name, mailing address, phone number, 
and e-mail address, if available. 
3.	 Circle your answers to the questions. To receive your continuing education credit, you must answer all of 
the questions. 
4.	 Sign and date the posttest. 
5.	 Return the evaluation questionnaire and posttest, no later than October 24, 2005, to CDC by mail or fax: 
Mail	 or Fax 
Continuing Education Coordinator  770-488-4178 
Division of Toxicology and ATTN: Continuing Education Coordinator
 Environmental Medicine, ATSDR 
1600 Clifton Road, NE (MS F-32) 
Atlanta, GA 30333 
6.	 You will receive an award certificate within 90 days of submitting your credit forms. No fees are charged for 
participating in this continuing education activity. 
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Case Study 
A 55-year-old female child care worker comes to your office concerned 
about a nontender thyroid mass that has slowly grown over the last 2 
years. She is worried that this condition could be passed on to her 
daughter, who is pregnant. 
Your patient was born in 1945 in Washington State. She grew up on a 
farm near the Hanford Nuclear Reservation, where her father worked as a 
machinist during World War II. The family history reveals that the woman 
lives with her husband of 41 years; her daughter, born in 1963, who is 6 
months pregnant; and her daughter’s husband. They have lived in your 
community for the last 12 years, in a single home in a low income area of 
town. 
The patient’s past medical history is noncontributory, and her family 
history is unremarkable. Her father died at age 84 of a myocardial 
infarction, and her mother died of colon cancer at age 77. The patient has 
no family history of thyroid disease or of other endocrine disease. She has 
two brothers and a sister; all are reportedly in good health. 
Your patient does not have symptoms consistent with hyperthyroidism or 
hypothyroidism; does not smoke and has not smoked in the past, but she 
occasionally drinks alcohol. She does not have any past workplace or 
hobby chemical exposures, and she has not received any therapeutic 
radiation exposures. 
Challenge Question 
(1)	 What have been the main sources of I-131 in the environment? 
Exposure Pathways 
“If the levels of environmental I-131 ... were released now instead of in 
the late 1940s–1960s, contaminated food quarantine, and emergency 
evacuation of many parts of the country would occur. The population 
would be outraged. A national health emergency would be declared. 
Congress would pour monies into health care and other help for those 
exposed. Ours may be exposures of the past, but those of us exposed as 
children, when we were most vulnerable to radioactive harm, are still alive 
and some of us have developed exposure health outcomes. We must not be 
discounted....” 
Testimony of a Hanford community member exposed to I-131 
(Hanford, Washington). 
A 55-year-old female presents 
with a nontender thyroid mass 
that has slowly grown over the 
last 2 years. 
Pretest 
(a)	 Which organ system is 
considered the critical organ 
for exposure to I-131? 
(b)	 What are the main routes of 
human internal exposure for 
I-131? 
(c)	 What are the most significant 
health effects from exposure to 
I-131? 
(d)	 Which group is most at risk for 
health effects from exposure to 
I-131, and why? 
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I-131 is radioactive, has an 
8.03 day half-life, and emits 
beta and gamma radiation. 
I-131 is normally present at 
low levels in hospital nuclear 
medicine departments, in 
patients administered 
radioactive iodine in the last 
3 months, and in releases from 
nuclear power plants. 
I-131 is produced during 
nuclear fission, which occurs 
during the operation of nuclear 
reactors or detonation of a 
nuclear bomb. When uranium 
or plutonium atoms undergo 
fission, about 
1.5%–2.0% of the fission 
products become I-131. 
The main sources of I-131 in 
the environment have come 
from nuclear power plant 
releases and from the 
production and testing of 
nuclear weapons. 
The highest levels of combined 
I-131 releases occurred 
between the early 1940s and 
mid-1960s. 
During the Cold War, national security policies prevented government 
authorities from disclosing the risks and health hazards associated with 
living near or working at weapon production facilities. These facilities 
released harmful levels of radiation into the environment. 
Many people in the United States, especially those living near or working 
at weapon production facilities, such as the Hanford Nuclear Reservation, 
were unknowingly exposed to multiple sources of I-131, including fallout. 
The Nevada Test Site (NTS), which was used to test nuclear weapons, 
produced considerable amounts of fallout, which exposed most of the 
American population. The existing national security policies kept that 
information from reaching the American public. 
This case study focuses on iodine 131 (I-131) because large amounts of 
this isotope were released during the production and testing of nuclear 
weapons. Iodine 127 (I-127) is the only naturally occurring iodine 
isotope, and it is the only nonradioactive (stable) iodine isotope. All other 
iodine isotopes (I-123, I-125, I-129, I-131, and I-135) are radioactive. 
Only I-131 and I-135 are associated with medical administration. 
The Legacy of I-131 in the Environment 
In the United States, past releases of I-131 have occurred at fuel 
reprocessing plants and some weapon production facilities of the 
Department of Energy (DOE). Since 1944, when the first production 
atomic reactor came into service, large amounts of I-131 have been 
periodically released into the atmosphere. I-131 was released to the 
atmosphere as a gas during nuclear weapons production (1945–1980s), 
aboveground nuclear tests (1951–1962), medical isotope production, 
medical administrations to patients, and unintentional releases. Multiple 
releases over time could have maintained constant or repetitive high levels 
of radioactivity, particularly around weapon production facilities. The 
highest levels of combined I-131 releases occurred from the early 1940s 
through the mid-1960s. 
The annual dose of background radiation received by an average person in 
the United States comes from the following sources: radon gas, 55%; 
internal radiation, 11%; cosmic rays, 8%; terrestrial radiation, 8%; and 
manmade products, 18%. Less than 1% of the radiation from manmade 
products comes from nuclear power plant releases and fallout. Typically, 
little of this dose is from I-131 because of the short half-life of the 
element: it decays (loses its level of radioactivity) rapidly and rarely exists 
at any meaningful level in the environment. However, this changes if a 
major nuclear release occurs. When a nuclear bomb detonates or nuclear 
power plant fuel melts and causes an explosion, the volatile I-131 produced 
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[6.2 miles]) by the intense heat, and is subsequently swept by the winds. 
I-131 can be deposited on the ground as dry deposition (I-131 adsorbs to 
particulates in the air and drops to the ground) or as wet deposition (I-131 
dissolves in atmosphere moisture, some of which becomes rainwater and 
falls to the ground). The initial quantity released determines the 
significance of the fallout. Persons living in the direction in which the 
wind blows are referred to as “downwinders.” Many of the persons living 
downwind from the Hanford Nuclear Reactor could have received 
multiple exposures over time. 
Total releases of I-131 worldwide equal 24,000,000,000 curies. The 
curie, or Ci, is the measurement for the rate of radioactive decay. If you 
would like more information on general ionizing radiation principles, 
please see ATSDR’s Case Studies in Environmental Medicine: Ionizing 
Radiation (ATSDR 1993a). 
Worlwide, major significant I-131 releases ocurred at the following 
locations. 
Total Estimated Amount 
of I-131 Released From 
the Site (in curies) Site Time Period 
150,000,000 Ci Nevada Test Site, Nevada 
50,000,000 Ci Chernobyl (former Soviet Union) 
740,000 Ci Hanford Reservation, Washington 
60,000 Ci Savannah River Site, South Carolina 
8,000–42,000 Ci Oak Ridge National Laboratory, Tennessee 
20,000 Ci Windscale, United Kingdom 








The peak years for the releases at the Hanford Nuclear Reservation were 
1944–1947 (92%), with minimal releases after 1947, except for two peaks 
in December 1949 (the Green Run) and May 1951 (filters removed). The 
largest I-131 releases from the Oak Ridge National Laboratory occurred 
between 1952 and 1956. An April 29, 1954, accident released 105 to 500 
Ci over 2½ hours, accounting for about 6.5% of the total release for 1954. 
The Nevada Test Site had 90 nuclear tests that released almost 99% of the 
total I-131 released into the atmosphere from 1952 through 1957. The 
Windscale release in the United Kingdom in 1957 was caused by a fire 
in the graphite moderator of an air-cooled plutonium production reactor. 
The Three Mile Island release in Harrisburg, Pennsylvania, in 1979, 
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The activity of I-131 (quantity 
of radioactive material 
present), the exposure route, 
and the individual’s age are 
factors that determine the 
exposure dose from radiation. 
Infants’ and children’s 
increased rate of growth and 
development make them more 
vulnerable to radiation 
exposures. 
Ingestion of contaminated milk 
has been the major I-131 
exposure pathway for humans. 
The concentration of I-131 in 
milk from goats and sheep is 
10 times higher than the 
concentration in cow’s milk. 
released 15–21 Ci of I-131 into the atmosphere. During and after the 
explosion and fire at the Chernobyl nuclear plant, large amounts of 
radioactive materials were released over a 10-day period, with 25% of 
the total amount released in the first day. These materials were 
subsequently spread over parts of Europe and the rest of the world by 
wind. 
Challenge Question 
(2) Why is dietary intake information important for assessing the 
patient’s exposure to I-131? 
Exposure Route 
The amount of I-131 available to expose a person after a release depends 
on the 
amount released 
distance between the populated area and the place of the release 
height of the release, and 
meteorologic conditions at and after the time of the release. 
The exposure pathway of greatest public health significance is the 
deposition of I-131 on pasture grasses, followed by the ingestion by cows 
or goats and the subsequent consumption of contaminated milk and fresh 
dairy products by humans. 
Exposure begins immediately for persons in the immediate vicinity of a 
nuclear release who are in the plume (the visible or invisible cloud of 
contamination). Internal exposure by inhalation occurs for persons inside 
the plume. External exposure occurs while the person is in the plume or 
on land left contaminated by fallout from the plume. Internal exposure by 
ingestion occurs when persons eat food that is contaminated with the 
fallout. The oral pathway is the main route of internal I-131 exposure for 
people. Milk is the major source of internal exposure. 
Dietary intake of iodine before exposure is important because a relative 
iodine deficiency increases the thyroid uptake of I-131. After exposure, 
the most critical dietary information needed is the amount and type of 
milk and milk products consumed, their I-131 concentrations, and the 
time they were consumed relative to the time of the release. 
Goat’s milk and sheep’s milk contain approximately 10 times the 
concentration of radioiodine found in cow’s milk. Inhalation, especially 
near releases of I-131 in the absence of rain, is another route of internal 
exposure. However, doses to humans from inhalation and from ingestion 
of plants, animals, or water are usually small in comparison. Figure 1 
shows the exposure pathways of I-131 from the environment to humans. 
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Figure 1. Exposure Pathways of I-131 From Environment to Humans 
Acute exposure to I-131 
Acute exposure to I-131 today could occur from unintentional or 
intentional releases. 
Public exposure to I-131 or contamination of soil, food, or water by 
I-131 engenders intense fear. The emotional and psychologic stresses 
resulting from exposure should be recognized and addressed early in 
a radiation incident. 
Explosion of a nuclear bomb produces a small amount of local I-131 
fallout; the remainder distributes over large distances, with only 10% 
making its way to the surface before transforming to stable xenon 131 
(UNSCEAE 2000a, 2000b). The less intense heat from a nuclear reactor 
release allows higher local I-131 fallout. 
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Incidence of thyroid cancer 
depends on many factors, 
including thyroid dose and age 
at the time of exposure. 
National Cancer Institute 





The current main sources of I-131 exposure would be a localized 
hospital accident, a major nuclear power plant release involving melted 
fuel, or an aboveground atomic bomb detonation. The resulting iodine 
levels along the plume path would vanish over a period of a few days to 
months depending on dilution and radioactive decay. 
Doses of I-131 that result from medical procedures, including 
therapeutic thyroid ablations, release low levels of radiation in hospital 
nuclear medicine departments. Therapeutic thyroid ablations have a 
mean thyroid dose of 10–100 Gray (Gy) to the patient, which is 
equivalent to a radiation absorbed dose (rad) of 1,000–10,000. These 
ablations significantly exceed an entire year’s worth of background 
radiation. Patients undergoing this procedure release low levels of 
radiation for about 3 months. 
Challenge Question 
(3) Which age groups are the most sensitive to I-131 exposure? 
Who’s At Risk 
During 1945–1962, when they were young children (and more vulnerable 
than adults to radiation exposure), many persons in the United States were 
exposed to radiation fallout from I-131 from multiple sources. Those 
exposures put those persons at risk for thyroid and parathyroid disease and 
cancer of the thyroid. 
Any person who was a child under the age of 10 between 1945 and 1962 
in the United States and who drank milk should be considered potentially 
exposed to I-131. People who lived near or around weapons production 
facilities, especially downwinders, are at risk for having received higher 
levels of exposure to I-131. 
More detailed information on how Americans were exposed to I-131 is 
available from the National Cancer Institute (NCI). The institute provides 
free print materials and maintains a Web site on I-131. 
Epidemiologic studies on thyroid cancer and I-131 at Chernobyl 
confirmed that the risk for thyroid cancer is dependent on the absorbed 
dose, the age and location of persons at time of exposure, and the absence 
of immediate iodine prophylaxes for I-131 exposure. A strong relationship 
exists between the incidences of thyroid neoplasia, hypothyroidism, and 
autoimmune thyroiditis and the received dose. In the most contaminated 
area after the nuclear release at Chernobyl, thyroid cancer incidence was 
significantly higher compared with other regions. There are no earlier 
studies comparable to those for Chernobyl because no studies were 
conducted around U.S. weapon production facilities when I-131 was 
released. 
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Age is a factor for exposure to I-131 because of the differences between 
thyroid doses for children and adults. The dose to children is much higher 
than that to adults because the thyroid mass in children is smaller, and 
because milk, as the main route of contamination, is consumed in higher 
quantities during childhood. For an equivalent uptake of I-131, a child’s 
thyroid receives a higher radiation dose because the same amount of 
energy is deposited in a smaller tissue mass (more energy per gram = 
higher dose). For newborns, the thyroid dose is about 16 times higher than 
that for adults for the same ingested radioactivity; similarly, the absorbed 
dose is about 8 times higher for children under 1 year old and 4 times 
higher for children 5 years old. 
Most of the immigrants from the former Soviet Union who came to the 
United States during the 1990s came from the Ukraine. Many of them 
came from areas that had been contaminated with I-131 during and after 
the Chernobyl explosion. Therefore, many of them—some of whom were 
children at the time—have been exposed to I-131. 
During pregnancy, the maternal thyroid has an increased rate of I-131 
uptake, especially during the first trimester. I-131 crosses the placental 
barrier. During the second and third trimesters, the fetal thyroid takes up 
and stores iodine in increasing amounts. During the first postpartum 
week, thyroid activity increases up to fourfold. This critical period lasts 
for a couple of days. Infants and children are at high risk from radioiodine 
exposure because their thyroids are small. This risk decreases as children 
age, although it continues until they are about 
20 years old. About one-quarter of the iodine ingested by the mother is 
secreted in breast milk, which adds an additional risk factor for the breast-
feeding infant. 
The geographic distribution of persons exposed to I-131 is important for 
three reasons. First, the risk is higher for those in rural areas because fresh 
milk is often consumed. This is important when the milk is produced from 
a contaminated pasture. The delay between the production and 
consumption of milk contributes to decreasing radioactivity for urban 
populations. Second, the risk is higher for populations with endemic 
deficiency of iodine. I-131 absorption is higher for these populations. 
Third, different types of milk and dairy products are consumed in some 
rural areas. In goat’s milk and sheep’s milk, I-131 concentrations are up to 
10 times higher than in cow’s milk for the same concentration of I-131 in 
the pasture. 
Challenge Question 
(4) Which organ is the critical target organ for exposure to I-131? 
Children are the most sensitive 
group for exposure to I-131. 
Special considerations exist for 
pregnant women and nursing 
mothers. 
Drinking fresh versus 
pasteurized milk leads to a 
higher dose of I-131. 
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The critical target organ for
 




Radiation dose and health risk must be calculated from continued 
exposures. The radiation dose from internalized I-131 is estimated on the 
basis of the following: 
activity deposited in the lungs and ingested (quantity of radioactive 
material measured in units of Becquerels or Curies); 
I-131’s chemical form and physical properties; 
the types, energies, and intensities of the emitted radiation; 
physical and biologic half-lives; 
the thyroid mass (which is age dependent); and 
the thyroid uptake fraction (based on diet and metabolism). 
With chronic exposure, the half-life of the radionuclides released becomes 
less relevant because new releases occur continuously. Many of the earlier 
off-site radiation exposures from nuclear weapon production facilities 
were chronic. In this case study, the term “dose” is used to refer to the 
radiation dose (the amount of energy deposited in tissue). The exposure 
dose depends on an individual’s risk factors (for example, age at time of 
exposure and the consumption of milk and milk products). 
The thyroid gland uses 
iodine to produce thyroid 
hormones which help 
regulate growth and 
metabolism. Iodine has a 
strong affinity for the 
thyroid gland, which is 
the critical target organ 
for exposure. Iodine is 
readily absorbed from the 
gastrointestinal tract and 
lungs into the 
bloodstream. Most of the 
iodine that enters the 
body quickly becomes 
systemic (EPA 1988), 
with approximately 30% 
depositing in the thyroid. 
Exposure to I-131, 
especially in childhood, increases the risk for hypothyroidism, thyroid 
nodules, and cancer. 
Illustration of the thyroid gland. 
Source: National Cancer Institute. 
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The metabolism of iodine is linked closely with the functional activity of 
the thyroid. The portion of systemic iodine that redistributes to the thyroid 
ranges from 20% (for hypothyroidism or iodine-rich diets) to 75% (for 
hyperthyroidism or iodine-deficient diets), with an average of 30%–50% 
for normal diets. The rest is excreted via urine. The moderate to severe 
iodine deficiency in the area near Chernobyl was a predisposing factor 
that caused thyroid doses to be higher than doses in regions where iodine 
uptake was normal. 
Thyroid Dose Due to Internal Radiation 
Estimating the radiation dose delivered by I-131 radiation to either the 
thyroid or the whole body involves multiplying the activity inhaled or 
ingested by an age-specific dose factor. Activity inhaled is the product of 
the mean air concentration of I-131, respiratory rate, and exposure time. 
Activity ingested is the product of the mean concentrations of I-131 in 
both food and water and the amounts of each consumed. These 
concentrations are functions of time delays between production and 
consumption as well as the geographic pattern of air concentration and 
fallout distribution. If the I-131 exposure was chronic, daily totals must be 
calculated and added using appropriate formulas and methods. 
A child’s thyroid dose from ingestion can be up to 20 times that of an 
adult because the same amount of energy is deposited in a smaller tissue 
mass. A child’s thyroid dose from inhalation can be twice that of an adult, 
and is 15–20 times higher than the overall dose to the rest of the body. 
Children living in the maximum exposure area of the Hanford Nuclear 
Reservation were estimated to have received doses that were 10 times the 
estimated dose of adults over the same period. 
Factors Affecting the Internal Thyroid Dose 
Produced by Milk Consumption 
Four factors can affect the internal contamination dose of persons who 
ingested milk containing the same I-131 concentrations. 
1. Time between production and consumption. Because of the short 
half-life of I-131, even a short delay caused by the processing 
and transport of milk can decrease the radioactivity of ingested 
milk. This factor played an important role in past releases, 
depending on whether a population was urban or rural; in 
general, urban populations consumed processed milk transported 
from farms, whereas rural populations consumed unprocessed 
fresh milk. Most populations today consume processed milk. 
2. Rate of consumption of fresh milk or of dairy products such as 
cheese. It is important to take into account that milk from cows, 
Hyperthyroidism or iodine 
deficiency results in increased 
uptake of I-131. 
Thyroid dose from ingestion of 
I-131 can be 10 times higher 
for newborns than for adults. 
Thyroid dose from inhalation 
of I-131 can be two times 
higher for infants than for 
adults. 
Thyroid dose can be 15–20 
times higher than the overall 
dose to the rest of the body. 
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Thyroid nodules, neoplasia, 
hypothyroidism, and 
autoimmune thyroiditis with or 
without hypothyroidism are 
the main effects of internal 
exposure to I-131. 
Benign neoplasms are more 
common than malignant 
neoplasms. 
goats, and sheep contain different levels of I-131, and that 
goat’s and sheep’s milk have the highest concentrations. 
3. Age and sex of exposed groups. Children and older people 
consume more milk than other groups do. Age at time of 
exposure is an important factor that influences individual thyroid 
dose. Because the infant’s thyroid is small, the dose conversion 
factor for milk consumption is strongly dependent on age. After 
age 50, the thyroid mass and the capacity for uptake of iodine is 
gradually reduced. During pregnancy, the uptake of iodine is 
slightly increased because of the relative iodine deficiency of the 
body. 
4. Geographic distribution of population related to the factors 
affecting thyroid dose (residence in relation to release or wind 
pattern). 
Physiologic Effects 
Persons exposed to releases of I-131 involving melted fuel at nuclear 
power plants, from production of nuclear weapons, and from fallout from 
aboveground detonation of atomic bombs have a higher risk for 
developing thyroid cancer or thyroid disease, or both, than do unexposed 
populations. In particular, persons exposed during childhood received 
higher doses, which in many cases were repetitive over time. These 
persons were more vulnerable than were those exposed as adults. 
Radiation causes health effects when either enough cells are killed quickly 
enough to disrupt tissue function (acute health effects) or damaged cells 
are incompletely repaired but still viable (carcinogenic, tumorigenic). I­
131 radiation might affect cells in the thyroid gland, leading to 
hypothyroidism or thyroiditis, or might cause benign or malignant thyroid 
tumors and nodules. The thyroid gland has one of the lowest cell-
proliferation rates of body tissues, and its regenerating ability is also low. 
Thyroid Tumors 
Even in the absence of exposure to I-131, thyroid tumors are the most 
common endocrine neoplasms. Thyroid tumors are usually nodules 
localized to the thyroid gland, and are often palpable on examination of 
the anterior neck. I-131 exposure increases the risk of thyroid nodules and 
cancer. Thyroid cancer is rare. The mean rate of spontaneous thyroid 
cancer is one in 1 million for children (10 in 1 million for adults), with a 
female-to-male ratio of 3 to 2. The increased risk for thyroid cancer is 
especially important for exposures to I-131 during childhood. The 
incidence of thyroid nodules increases with age. However, thyroid cancer 
in children often presents at a more advanced stage than in adults: more 
distant metastases, more lymph node involvement. The risk of recurrence 
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is higher in children, but the death rate (at least over 20 years) is much 
lower in children than in adults. 
When identifying those nodules that are likely to be malignant, a careful 
history is crucial. The history should include past medical history, 
occupational history, environmental (exposure) history, family history 
including dietary exposure, and social history. Of particular importance is 
a history of external radiation exposure to the head, neck, or upper 
mediastinum in infancy or childhood. 
Exposure of the thyroid gland to moderate to high doses (from 6.5 to 
2,000 centigray) of I-131 linearly increases the risk for thyroid cancer. 
Nodular disease occurs in about 20% of these patients, but it might not be 
apparent until 30 or more years after the initial exposure. The risk for 
thyroid neoplasm has been correlated directly with younger age at 
radiation exposure, radiation dose, and sex. (A male patient with a nodule 
should be regarded with greater suspicion because more women have 
thyroid cancer—by a ratio of 2:1—and women have more thyroid 
disease—by a ratio of about 8:1.) Thyroid nodules in children and elderly 
patients are more likely to be malignant. 
Excesses of thyroid nodules and cancer (including 1,800 cases of thyroid 
cancer) reportedly occurred from the Chernobyl nuclear power plant 
release. These results might have reached higher levels than expected due 
to low dietary intake of iodine in the region and high endemic rates of 
goiter. 
“Further research related to iodine-131 would be useful in several areas 
including the risk posed by low levels of exposure, possible differences in 
radiation-related and naturally occurring thyroid cancers....” (Committee 
on Thyroid Screening 1999). The Hanford Thyroid Disease Study found 
no dose-response relationship. An individual’s increased risk, however, 
cannot be ruled out. The Hanford thyroid dose estimates were based on a 
dose reconstruction model using historical records and assumptions that 
result in uncertainty of doses. 
Thyroid Cancer After X-Ray Exposure 
Several cohorts of pediatric patients irradiated in head and neck area for 
thymus hypertrophy, tinea capitis, and chronic tonsillitis have been 
studied. These studies suggested three findings. First, the thyroid of 
children is more sensitive to carcinogenesis than is the thyroid of adults. 
Second, the delay between the external irradiation and the appearance of 
the cancer is at least 10 years (average delay 20 years). Third, the dose-
response curve is linear for persons exposed before 15 years of age 
(even down to 0.1 Gy [10 rad]). The excess relative risk per unit of 
5%–10% of palpable nodules 
are thyroid cancer; the 
remainder are benign thyroid 
nodules. 
More information on ionizing 
radiation, taking exposure 
histories, pediatric environmental 
health, and reproductive and 
developmental hazards is readily 
available in other ATSDR case 
studies (ATSDR 1993a, 1993b, 
2001, 2002). 
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Increased risk for thyroid 
neoplasm remains elevated for 
at least 40 years after exposure. 
Elevated levels of psychologic 
stress, which can lead to 
increased risk of depression, 
anxiety, and posttraumatic 
stress disorders in some 
people, can occur after 
incidents involving nuclear 
releases. 
exposure (ERR/Gy) for childhood exposure is 7.7 (95% confidence 
interval, 2.1–28.7). 
Reproductive and Developmental Effects 
From Therapeutic Uses of I-131 
I-131 has become a standard treatment for thyroid ablation in persons 
with hyperthyroidism or thyroid cancer. At least seven case reports and 
small case series on adverse reproductive outcomes of medical I-131 use 
have been published; however, sufficient information was not provided to 
determine whether the fetus was exposed to I-131 radiation and, if so, to 
what extent. The authors concluded that although the abnormalities found 
could not be directly attributed to the therapy, it is prudent to avoid 
pregnancy for 1 year after radiation treatment. 
Other Effects 
Thyroid exposure to either internal or external radiation might trigger an 
immune response. Changes in thyroid autoimmunity after I-131 therapy 
have been attributed to the production and release of autoantigens as a 
result of radiation damage. 
Acute/Recent Exposure 
Acute radiation thyroiditis occurs within 2 weeks after high exposure to 
I-131 and is characterized by local pain and tenderness over the gland. 
Occasionally, significant systemic symptoms have been associated with a 
massive release of stored thyroid hormone. This syndrome can require 
treatment with anti-inflammatory agents and beta-adrenergic antagonist 
agents. Clinically significant acute radiation thyroiditis is unlikely to 
occur at thyroid I-131 doses below 20,000 rad. Radioactive iodine can 
accumulate during pregnancy in the fetal thyroid and cause its permanent 
ablation. Because of the risk for fetal exposure to I-131, women of 
childbearing age must take a pregnancy test before undergoing medical 
radioiodine treatment. 
Psychosocial Effects 
A nuclear release or known past exposure from any type of radiation can 
lead to increased psychologic stress because of the invisible nature of the 
event and concern for serious health-related effects from a radiologic 
contaminant. Results from studies in communities affected by previous 
nuclear releases, such as Three Mile Island (TMI), showed that area 
residents experienced long-term elevations of stress with increases in 
community rates of subclinical depression, anxiety, demoralization, and a 
heightened perception of risk. Indeed, the high levels of psychosocial 
stress in communities affected by the TMI release remained elevated for 
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6 years after the release and did not return to normal until 10 years after 
the incident (Baum et al. 1983). 
Health care providers may hear concerns from people who might have 
been exposed to radioactive releases from nuclear tests or facilities. It is 
common for these people to talk about uncertainties about their health 
concerning previous or present exposure and the effect on their health. 
Patients’ health concerns may center around whether they will get ill 
and—if so—when, what caused the illness, whether the illness can be 
diagnosed properly, and what its prognosis, treatment, and financial 
impact will be. Because of fear of cancer and the uncertainty of when or 
whether it might occur, patients can have emotional stress, risk for 
developing anxiety, and depression (Vyner 1988). 
Social consequences to exposure to radiation can also occur. Many of the 
men and women exposed in Nagasaki and Hiroshima during World War II 
were perceived as “damaged” and shunned for marriage because of the 
potential for “damaged genes.” 
Challenge Questions 
(5) What would you include in your patient’s exposure history? 
(6) 	What is the procedure of choice to study a palpable nodule of the 
thyroid gland? 
Clinical Evaluation 
Because I-131 concentrates in the thyroid gland, evaluation of a patient 
exposed to I-131 centers on diseases of the thyroid. Exposure to I-131 can 
cause thyroiditis, hypothyroidism, and thyroid neoplasms. The patient 
might have a variety of symptoms related to exposure or might have 
health-related concerns about past exposure. The occurrence of thyroid 
diseases caused by exposure is indistinguishable from those that occur 
spontaneously. The patient might not have specific knowledge of the 
nature of the exposure, which might have occurred years earlier. 
A history and appropriate physical examination supplemented with 
laboratory investigation, imaging studies, and fine-needle aspiration 
biopsy (FNAB) of the nodules in question should provide the clinician 
with sufficient information to assess the likelihood of malignancy and to 
advise his or her patients of appropriate treatment options. 
Ultrasound can find many nodules not palpable during the physical 
examination. Ultrasound is being used for thyroid monitoring programs in 
other countries where some of the population has been exposed to 
I-131 releases. However, the use of thyroid ultrasound in mass 
Most people want to receive 
information as quickly as 
possible after notification of a 
nuclear or chemical release. 
They want public health 
officials or their primary care 
providers to give them advice 
about potential health risks and 
what actions to take to prevent 
serious consequences of their 
exposure. Timely and correct 
information is key to 
preventing stress and relieving 
its psychosocial effects. 
Mothers are especially 
susceptible to psychological 
effects because of their 
concern about the effects of 
radiation on their children’s 
health. Pregnant women have 
added worry about risks to 
their unborn children. 
“Early detection of a change in 
health status is the most effective 
way to lessen the burden of more 
advanced disease and enhance 
survival.” 
Dr. Barry L. Johnson, assistant 
surgeon general and ATSDR 
assistant administrator, 
congressional testimony on the 
National Cancer Institute’s 
Management of Radiation Studies 
(Congressional testimony 1998). 
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History and physical exam 
should focus specifically on 
signs and symptoms related to 
the thyroid gland. 
screenings for thyroid nodules is controversial because of its high 
sensitivity and low specificity. 
If a nodule is identified, fine-needle aspiration biopsy (FNAB) performed 
by an experienced physician with appropriate training and experience is 
the procedure of choice. If the cytology of the nodule is malignant or 
nondiagnostic, the patient should be referred to a specialist for surgical 
resection. 
Patient History 
The medical history should include prior endocrine, thyroid, or 
parathyroid problems; prior thyroid diagnostic tests and treatments; and 
history of thyroid or neck surgery. Information about changes in the size 
of the nodule or nodules can assist in determining the etiology. Nodules 
that are unchanged for years are probably benign, but nodules that grow 
rapidly demand careful evaluation and are more likely to be associated 
with parathyroid disorders. 
A family history of Hashimoto thyroiditis, benign thyroid nodule, or 
goiter favors a diagnosis of benign disease. Other history that suggests 
benign disease includes symptoms of hypothyroidism or hyperthyroidism, 
and pain or tenderness of the nodule. Risk factors for malignant disease 
can include a family history of thyroid carcinoma or multiple endocrine 
neoplasia type II; the patient’s age (<20 years or >70 years); the patient’s 
gender (male); recent changes in voice, breathing, or ability to swallow; 
and a childhood history of head, neck, or upper mediastinum radiation 
exposure. 
Exposure History 
An exposure history includes previous childhood head, neck, and upper 
mediastinum radiation exposure; previous residences (downwind from or 
proximity to nuclear testing or release sites); dietary habits since 
childhood; source of drinking water; occupational history; and hobbies. 
Milk consumption and source are important risk factors (for example, 
fresh versus processed milk; milk from a cow, sheep, or goat). The patient 
should be asked about symptoms consistent with hypothyroidism, 
hyperthyroidism, and disorders of calcium metabolism. 
Exposure to I-131 could be indicated by the patient’s answers to questions 
in the exposure history relating to the following: 
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previous childhood head, neck, and upper mediastinum radiation 
exposure 
previous residences 
dietary habits since childhood 
milk consumption and source. 
Populations exposed to I-131 can have a higher prevalence rate for thyroid 
nodules than populations that have not been exposed. Patients, especially 
infants and children who have been exposed to significant doses of I-131, 
are more susceptible to the associated negative health effects. The major 
clinical concerns after significant I-131 exposure include hypothyroidism 
and thyroid cancer. 
Physical Examination 
Physical examination of the neck and thyroid should evaluate the gland’s 
size, presence of nodules, and the cervical lymph nodes. The thyroid 
gland should be inspected for shape, consistency, and areas of tenderness. 
Local examination of the neck is best accomplished with the patient 
seated in good light with the neck moderately extended. To facilitate the 
examination, the patient should be given a glass of water to assist 
swallowing. Auscultation of the neck provides some indication of the 
vascularity of the gland. A systolic or continuous bruit is usually 
associated with hyperthyroidism. The parathyroid glands are also 
susceptible to the effects of I-131 exposure. The presence of cervical 
lymphadenopathy, especially in children, might be the first sign of thyroid 
cancer. In general, a nodule 1 centimeter (cm) or greater should be 
palpable on physical examination. 
Signs and symptoms that should prompt concern include rapid 
enlargement of a previous or new thyroid nodule, unilateral vocal cord 
paralysis, dysphagia, and dyspnea. A solitary nodule in an otherwise 
normal gland should raise the suspicion of thyroid carcinoma. A lesion is 
probably malignant if it is adherent to the surrounding structures (trachea 
or strap muscles). Palpable cervical lymphadenopathy adjacent to a 
thyroid nodule is suspicious for a carcinoma, or it might be the only 
indication of metastatic thyroid cancer when no thyroid nodule is 
palpable. 
It would be appropriate to consult an internist, endocrinologist, a surgeon 
specializing in thyroid surgery, or an interventional radiologist when 
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Initial laboratory evaluation 
should include a serum thyroid 
stimulating hormone (TSH) 
level. 
Screening patients for thyroid 
effects of I-131 is different 
from evaluating a known 
thyroid nodule. 
assessing a patient with a suspicious thyroid nodule and an abnormal 
screening evaluation. These specialists can either assist with the 
interpretation of the screening results or formulate a management plan for 
the patient. (Information about specialists is available from the American 
Board of Medical Specialties, which has a Web site at URL: http:// 
www.abms.org/). 
Case Study (continued) 
The woman is a well-developed, mildly overweight, well-nourished 
female who looks her stated age of 55 years. Palpation of her neck reveals 
an ill-defined thyroid that is slightly tender diffusely with a homogenous, 
rubbery texture. A 1-cm nodule is just palpable in the left lobe. 
Auscultation of the neck reveals no bruits, either over the carotids or over 
the thyroid. No cervical nodes are palpable. Chvostek and Trousseau signs 
are negative. Hair and skin appear unremarkable, with perhaps the 
exception of some puffiness of the face. No evidence of mental dullness is 
seen. Deep tendon reflexes are normal without prolongation of relaxation 
phase. The rest of the examination is unremarkable. 
When requestioned about specific symptoms of hypothyroidism, your 
patient admits that she has felt a bit more tired lately. She has been 
constipated occasionally and intolerant of cold. She has gained weight 
despite eating less. She attributed these symptoms to aging and had not 
thought much about them. 
Challenge Questions 
(7)	 Which diagnostic tests are recommended for routine initial screening 
of thyroid function? 
(8) 	What additional tests could be obtained for the evaluation of a thyroid 
nodule? 
Laboratory Analysis 
No evaluation of the thyroid gland is complete without a structural 
assessment (physical exam) and a functional assessment (blood analysis 
to determine the TSH level). Thyroid function tests are mandatory for 
evaluation of a thyroid nodule; however, these tests do not differentiate 
between benign and malignant nodules. 
In screening programs, it is important to test for the noncancerous effects 
of I-131. The serum TSH level should be obtained to identify those 
patients with thyroid gland dysfunction. If TSH is abnormal, serum free 
thyroxine (FT4) and levothyroxine (T3) levels should be measured. Most 
patients with thyroid cancer are euthyroid (their thyroid glands function 
normally), and it is rare for a patient with thyroid cancer to have an 
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Chronic autoimmune thyroiditis can be found with an increased TSH 
level and a thyroid nodule or bilateral nodules. Serum antithyroid 
peroxidase antibody and antithyroglobulin antibody levels can assist in 
the diagnosis of chronic autoimmune thyroiditis. However, the diagnosis 
of chronic autoimmune thyroiditis does not exclude the presence of 
cancer within the thyroid gland. Serum calcium levels should be 
assessed because of the risk for hyperparathyroidism after I-131 
exposure. If the calcium level is abnormal, measure parathyroid 
hormone and phosphorus. 
Ultrasound is useful to determine the size and physical characteristics of 
a nodule once it has been identified. However, ultrasound cannot 
differentiate benign from malignant nodules and therefore is not required 
in the evaluation of a palpable thyroid nodule. 
Case Study (continued) 
Your patient’s lab results were as follows: 
A thyroid ultrasound showed a heterogeneous gland with multiple small 
cysts and one 1-cm x 1-cm cyst in the left lobe. 
Parameter Result Normal Range 
TSH 7.0 nanograms per milliliter (ng/mL) 0.36–4.7 ng/mL 
FT4 0.83 0.83–1.44 
T3 resin uptake 1.2 micrograms per deciliter (µg/dL) 0.8–1.2 µg/dL 
Calcitonin 15 picograms per milliliter (pg/mL) < 20 pg/mL 
Calcium 9.1 milligrams per deciliter (mg/dL) 8.5–10.4 mg/dL 
Ionized calcium 1.30 millimoles per liter (mmol/L) 1.16–1.32 mmol/L 
Phosphorus 2.9 mg/dL 2.8–4.6 mg/dL 
Parathyroid hormone 50 pg/mL 10–65 pg/m 
Challenge Question 
(9)	 What are the recommendations for managing a thyroid nodule found 
to be benign by FNAB in a patient with a history of exposure to I-131? 
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Fine needle aspiration biopsy 
is the procedure of choice for 
evaluating whether or not a 
thyroid nodule is malignant. 
Fine Needle Aspiration Biopsy 
The challenge to clinicians is to distinguish benign nodules from 
malignant tumors. The prevalence of clinical thyroid cancer in the general 
population is significantly less than 1%, and the majority of nodules are 
benign. Fine needle aspiration biopsy (FNAB) is the procedure of choice 
for evaluating a palpable nodule. The technique is simple and generally 
free of complications when performed by an experienced physician with 
appropriate training. If a nodule is found with ultrasound, the physician 
must differentiate between a simple cyst and a complex cyst. A simple 
cyst will require followup. A complex cyst must undergo an FNAB. If the 
results of the cytologic examination indicate the nodule is benign, no 
further testing is required but followup should be on an annual basis. 
Nondiagnostic results call for a repeat of the FNAB. Diagnosis of a 
malignancy or a probable malignancy requires surgery. (Figure 2 
illustrates the process of nodule evaluation.) 
Figure 2. Evaluation of a Euthyroid Nodule 
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FNAB is reportedly superior to all other techniques for diagnosing thyroid 
cancer. The use of FNAB can reduce the number of unnecessary surgical 
operations for suspicious nodules that prove to be benign. It is also the 
procedure of choice for evaluating a complex cyst after it has been 
identified on ultrasound imaging of the thyroid gland. Very few palpable 
thyroid nodules are actually simple cysts (defined as a cystic structure 
with no internal echoes and no evidence of thickening of the cyst wall). 
Most palpable thyroid nodules are solid nodules with cystic components. 
A simple cyst is almost always benign. Occasionally, cancer is found in 
the wall of the cyst. For this reason, recurrent cysts should be imaged by 
ultrasound. Surgical evaluation is indicated if evidence exists for a 
separate lesion or growth in the wall of the cyst. 
FNAB for cytology with ultrasound guidance is often a diagnostic 
procedure; when the nodule is cystic, FNAB might also be curative. A 
satisfactory aspirate specimen combined with an accurate cytology 
evaluation by a cytopathologist provides a reliable means of 
differentiating between a benign and malignant nodule in all but highly 
cellular or follicular lesions. FNAB does not allow for differentiating 
Hashimoto disease from lymphoma of the thyroid. This can be done using 
a combination of FNAB cytology and clinical evaluation. A 
“nondiagnostic” specimen should be followed up with a repeat FNAB. A 
nodule that gives persistently nondiagnostic FNAB results should be 
surgically removed. 
In general, 20% to 30% of patients are referred for surgical evaluation on 
the basis of FNAB cytologic features. 
Cytologic Assessment 
Diagnosis and classification of thyroid cancers are performed by cytology. 
The most efficient way of screening for thyroid malignancy in a patient is 
to elicit a thorough history and perform a careful physical examination, 
followed by an FNAB and interpretation of the specimen by an 
experienced cytopathologist. Neck ultrasound is an ideal technique for 
establishing whether a palpable cervical mass is within or adjacent to the 
thyroid, and for differentiating thyroid nodules from other neck masses 
such as cystic hygromas, thyroglossal duct cysts, and enlarged lymph 
nodes. Papillary thyroid cancer is the most common type of cancer found 
among the population exposed to I-131 releases in Chernobyl. 
Case Study (continued) 
The patient in the case study was diagnosed with mild hypothyroidism 
and prescribed levothyroxine (50 µg/day). She was seen 1 month later; test 
results revealed TSH of 3.1 ng/mL (normal 0.36–4.7 ng/mL). She had lost 
3 pounds and felt less tired. 
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Challenge Question 
(10)	 Are the patient and the rest of her family at increased risk for 
cancer? Is there increased risk for any other disease? Were there 
any risks to her daughter’s unborn child because of the patient’s 





Initial and Follow-Up Visits for Patients 
Identified as Exposed to I-131 
The major clinical concerns after significant I-131 exposure, especially in 
infants and children who are more susceptible than adults, include 
developing hypothyroidism and thyroid cancer. Currently, children who 
are born in the United States are screened at birth for thyroid function; 
therefore, no thyroid tests are necessary for children growing normally 
without other medical problems, unless they are exposed to significant 
doses of I-131. 
If a nodule is benign, the patient could be treated with T4 in a dose 
sufficient to suppress serum TSH, which will limit glandular growth. If 
the nodule decreases in size, the patient should be maintained on T4 
indefinitely and the nodule monitored with palpation and ultrasound. If 
the nodule persists while the patient is on T4 therapy, a repeat FNAB is 
necessary. If the nodule grows during T4 therapy, surgical resection is 
indicated. 
Distant metastasis is uncommon, but lung and bone are the most common 
sites. In the case of thyroid cancer that has metastasized to other organs, it 
is helpful to have additional pathology analysis to determine whether the 
cancer is a thyroid cancer or whether it originated from another organ. 
This is particularly important in the case of former nuclear workers who 
might be eligible for compensation only for cancer originating from 
certain organs, or for nonworkers who are seeking compensation through 
the legal system for exposure health outcomes. 
Approach to the Patient and Family 
To work effectively with patients, physicians need to understand that 
people who have been exposed to radiation are having normal, typical 
emotional responses that are to be expected under the circumstances. After 
any exposure, it is important that the psychologic support for the patient 
be combined with a risk communication plan to provide accurate 
information about the acute and delayed health effects of I-131. This will 
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Table 1. Summary of Initial and Follow-Up Visits for Patients Identified as Exposed to I–131 in 
Previous Years 
Exam Test Results Actions 
Initial patient visit 
Follow-up visit for a 
patient with a palpable 
thyroid nodule 
During future physical 
examinations 
Medical history 
Physical exam with 





protocol for ultrasound 
and FNAB 
Medical history update 
Serum TSH and 
calcium levels 
Physical exam with 
thyroid palpation 
History of exposure 
only with normal 
examination and 
screening tests 
Thyroid nodule found 
(1 cm or larger) 


















Thyroid nodule found 
(1 cm or larger) 
Educate patient on early warning signs 
of thyroid and parathyroid diseases. 
Begin screening workup. Schedule next 
visit. 
Obtain levels of serum calcium, 
parathyroid hormone (PTH), FT4, 
and antithyroid peroxidase antibodies. 
Refer patient to an endocrinologist, as 
appropriate. 
Redraw blood; if abnormal, test for 
PTH and refer to endocrinologist as 
appropriate. 
Schedule repeat exam in 1 year with 
palpation and thyroid function tests. 
Refer patient to an endocrinologist, as 
appropriate. 
Schedule next visit. See Figure 2. 
Schedule for evaluation by surgeon. 
Educate patient on early warning signs 
of thyroid and parathyroid diseases. 
Schedule for evaluation by surgeon. 
Begin screening workup. Schedule next 
visit. 
The frequency of examinations will depend on the presence of any thyroid abnormalities. For patients who have no 
abnormalities identified initially, no periodic visits are necessary but TSH should be tested when a physical is 
performed. For patients with abnormalities, the provider should schedule examinations at yearly intervals. 
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Most people affected by I-131 
exposure are psychologically 
healthy, functioning adults 
who are experiencing high 
levels of stress. 
Accurate information on the 
possible health effects of I-131 
is needed after exposures due 
to nuclear releases. 
give exposed persons some of the information they need to understand 
the event. To ensure that information is accurately and completely 
understood, it may need to be repeated over a period of days or weeks. 
Distribution of clearly written information, with references to the 
scientific literature, might also be useful. Provision of timely and correct 
information is one key to preventing stress and relieving psychosocial 
effects after notification of the potential health risks of I-131 exposure. 
Persons exposed to I-131, as well as family members of those exposed, 
need an opportunity to ask questions of health experts about the potential 
risk for present or future effects. Psychologic support should be continued 
after the immediate event because fear of possible future health effects can 
persist and might contribute to psychologic illness. 
Distress Versus Disease 
Most people will suffer normal emotional distress; only a few will develop 
psychologic illnesses depending on the circumstances of their exposure. 
Specific psychotherapeutic or psychopharmacologic treatments might also 
be useful to treat posttraumatic stress disorders, anxiety disorders, or 
depression that might occur in some patients in the aftermath of exposure. 
However, if depression occurs in a patient exposed to I-131, it is important 
to differentiate organically based mood changes possibly related to 
hypothyroidism from psychologically based depression related to stress 
about the exposure. Depression is a disorder, but can be a symptom. 
Symptoms similar to depression, such as a sad mood, lethargy, and lack of 
appetite, can be caused by an underlying hypothyroid condition, which 
must be diagnosed and treated correctly and not mistaken for depression. 
Consultations between endocrinologists and psychiatrists are 
recommended for these complex situations. 
Challenge Question 
(11) How can you find out if potassium iodide (KI) is available to your 
community in case of an emergency? 
Acute Exposure 
To reduce internal exposure to I-131 by inhalation, residents of 
communities near a release could stay indoors with the doors and 
windows closed to keep contaminated air out of their homes. Moist towels 
can be laid on window sills and at the bottom of doors to reduce air 
infiltration. The exposure scenario determines the relative significance of 
the different pathways (Whicker and Pinder 2002). 
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Prophylactic Administration of Stable Iodine 
(Potassium Iodide) 
Potassium iodide (KI) is the preferred form of stable iodine. Thyroid 
uptake of I-131 can be reduced by more than 90% through an immediate 
oral dose of KI. Failure to administer KI within 2–4 hours after exposure 
to I-131 eliminates protection against the risk for adverse health 
outcomes. 
Taking KI just before or within 1 to 2 hours after exposure to I-131 can 
block more than 90% of the radioactive iodine uptake by the thyroid. This 
means that public health officials must notify the public and the health 
professional community of I-131 releases immediately. If KI is taken 
3 hours after acute exposure, approximately 50% of the thyroid uptake of 
I-131 is blocked. When KI is taken 4 hours after acute exposure, only 10% 
of the I-131 thyroid uptake is blocked. Taking KI more than 4 hours after 
exposure provides little protection unless the exposure to I-131 continues. 
Contraindications include allergies to iodine and must be considered 
before administering KI. Potassium iodate (KIO
3
) can also be used, 
although it might be associated with slightly more gastrointestinal 
irritation. Information on age-specific dosage recommendations is given 
in Table 2. Precautions and contraindications applicable to KI are found in 
Food and Drug Administration (FDA) guidelines (FDA 2001). To 
continue treatment, doses of KI should be administered once each day for 
7 to 14 days to prevent recycling of the I-131 into the thyroid. 
Table 2. Recommended Single Doses of Potassium Iodide (KI) as a 
Blocking Agent, by Age Group 
Fraction of Tablet 
Age Group 130 milligram 65 milligram 
Neonates (birth to 1 month) 1/8 1/4
 
Infants (1 month–3 years) 1/4 1/2
 
Children (3–12 years) 1/2 1
 
Adolescents and adults (12–40 years) 1 2
 
Adults over 40 years 0 0
 
For persons older than 40 years of age, the risk for radiation-induced 
thyroid cancer is extremely low, while the potential side effects of 
prophylaxis due to preexisting thyroid disease tend to increase. Adults 
over 40 therefore do not need to take potassium iodide as prophylaxis for 
exposure to I-131. In the United States, the FDA has recommended 
prophylaxis with stable iodine when the committed dose equivalent to the 
adult thyroid is expected to exceed 250 milliSieverts (mSv), the 
equivalent of 25 rem (Roentgen equivalent in man or mammal) (FDA 
Administration of potassium 
iodide (KI) can significantly 
reduce thyroid I-131 uptake. 
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The conversion of contaminated 
milk to powdered milk, cheese, 
yogurt, or ice cream allows 
I-131 to decay to lower levels, 
thus reducing radiation 
exposure. 
2001). Sale or use of KI for this purpose does not require a physician’s 
prescription. 
Current Nuclear Regulatory Commission (NRC) policy acknowledges that 
the use of KI is a protective measure for specific local conditions for 
populations exposed to I-131. It also states that KI is an inexpensive and 
reasonable supplement to sheltering and evacuation in case of a nuclear 
release. NRC policy requires that consideration be given to the use of KI 
in developing site-specific emergency plans. 
If you live within 50 miles of a nuclear facility (Emergency Planning 
Zones or EPZ) that produces or is capable of releasing I-131, you should 
work with your medical association, local or state public health 
department, emergency response organizations, and elected 
representatives to ensure that a stockpile of KI is available and a 
distribution plan is in place. Predistribution of sealed packets of KI tablets 
to residents within the EPZ, combined with educational materials, 
instructions, and engagement in exercises would enable a significant 
percentage of the at-risk population to efficiently undergo prophylaxis 
when so advised by public health officials. However, because 
predistribution is unlikely to completely reach the target or vulnerable 
population, supplemental stocks of KI tablets should be stored at strategic 
locations such as schools, hospitals, pharmacies, fire departments, and 
police stations. Individually sealed tablets of KI incorporated into a 
cardlike dose pack will be stable for 5–10 years, or possibly longer. 
The easiest way to reduce or eliminate internal exposure to I-131 during a 
release is to find an alternate food source of items produced outside the 
contamination zone. Contaminated milk can be made into cheese, yogurt, 
or ice cream; it can also be converted to powdered milk that can be used 
after the I-131 decays away. 
Challenge Questions 
(12)	 What are some of the factors that can affect the way an individual 
(or a community) perceives the risk of exposure to 
I-131? 
(13) 	How can you communicate information about the risks associated 
with exposure to I-131 to your patients and your community? 
Communicating About Risks 
During the Three Mile Island release in 1979, the population in the area 
perceived a high risk associated with the release. Poor management of the 
situation and poor communication with the population in the affected area 
led to mistrust and increased levels of psychosocial stress that remained 
elevated for many years. 
28 
Radiation Exposure From Iodine 131 
The field of health risk communication has developed science-based 
approaches for communicating effectively in high-concern, low-trust, 
sensitive, or controversial situations. Good risk communication involves a 
dialogue among all persons and groups concerned to communicate the 
nature and level of risk and the steps to take to change that level. The goal of 
risk communication is to increase knowledge and understanding, to 
enhance trust and credibility, and to resolve conflict. 
Risk communication is of critical importance in the evaluation and 
management of persons with concerns about past exposure to I-131. It 
involves the characterization of information with the involvement of 
individuals and communities who might have been exposed. These 
individuals and communities are stakeholders in the risk communication 
process. In this process the risks are effectively communicated, relieving 
tension and anxiety, improving subsequent communications, and 
increasing the effectiveness of risk management decisions. 
The perception of risk by individuals or communities can be affected by 
several factors other than how the risk is communicated. This includes 
cultural, social and economic level, geographic location, previous 
experience, and other variables inherent to the individual, such as 
personality. In matters of high concern and low trust, perception equals 
reality. Peter Sandman (1993) developed a framework for dealing with 
risk. Risks that are 
natural are more readily accepted than those that are man-made 
visible and avoidable are more readily accepted than those that are 
unseen and imposed by others 




familiar are more acceptable than risks that are exotic or unfamiliar. 
The public might be distrustful and upset because a real threat to their 
health has occurred. They expect to receive information about the incident, 
about who is exposed and what dose was received, and about how the 
exposure will affect their health. The level of trust a source has developed 
with a community will determine how credible the community will 
perceive the message to be. 
Empathy and caring, dedication and commitment, competence and 
expertise, and honesty and openness are important trust and credibility 
factors. Health care providers are among the top third in surveys on trust 
and credibility on health and environmental issues. 
Key issues within communities are health, safety, environment, quality of 
life, fairness, legality, and economics. The media has an important role in 
Effective risk communication 
allows the populations affected 
to improve decision making; it 
also can relieve tension. 
Perception of risk is affected 
by many factors and can be 
unrelated to actual risk. 
Good communicators establish 
trust by getting factual, timely 
information to the community 
and including all stakeholders 
early in the process. 
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communicating risks to the general public and should be included as 
partners in a risk communication plan. Government officials and health 
care and public health professionals often seek out the media, or are 
sought out by the media, to explain risk resulting from catastrophic 
events. A communications plan must be in place before such an event to 
maximize the opportunity to promptly and accurately inform the public. 
In communicating information about health risks, it is important for 
messages to be consistent. Coordinate with your local medical 
association, local or state public health department, emergency response 
organizations, and elected representatives to ensure that all segments of 
the community receive clear and consistent messages. 
Persons with concerns about exposure to I-131 might have fear and anger 
that need to be addressed in a timely manner by health care providers. The 
health care provider can encourage trust and credibility by getting the 
facts of the exposure straight, being forthcoming with information that 
meets the needs of the individuals, coordinating efforts with public health 
agencies, and avoiding giving mixed messages. 
In persons with concerns about I-131 exposure, great uncertainty exists 
about the risk. Uncertainty exists with respect to previous and present 
exposures, the dose received by individuals, the clinical significance of 
exposure and dose, and who might be legally and morally responsible for 
the financial costs of the exposure. The health care provider needs to 
anticipate this uncertainty to effectively help the patient recognize the 
risks. It is important to deal with the uncertainty; listen to and deal with 
specific concerns; convey the same information to all segments of your 
audience; and explain risk in language people understand, simplifying 
language and presentation, but not content. 
30 
 
Radiation Exposure From Iodine 131 
Standards and Regulations
 
Environmental Protection Standards 
The United States (FDA and EPA) and the World Health Organization 
(WHO) have issued standards that limit the amount of contamination in 
food, water, and air. 
Table 3 provides a summary of standards for environmental and 
occupational exposures to I-131. The FDA food concentration guidelines 
both (a) restrict the flow of contaminated food out of an affected area into 
the regional or global food supply and (b) set limits on local consumption 
of affected food and water. If limits are exceeded for the local population, 
uncontaminated food should be provided from outside the affected area. 
This also applies to drinking water with I-131 levels above EPA limits. 
Occupational limits for radionuclide exposure address ingestion, 
inhalation, and external exposure and are set by the Nuclear Regulatory 
Commission (NRC) for NRC licensees and by the Department of Energy 
for DOE facilities. The NRC limits for I-131 are as follows: 
2 X 10-8 µCi/mL (for occupational air exposure) 
2 X 10-10 µCi/mL (for effluent air to which the public could be exposed) 
1 X 10-6 µCi/mL (in effluent water), and 
1 X 10-5 µCi/mL (for monthly average releases to sewers from medical 
facilities). 
These NRC limits are intended to ensure that no worker exceeds 50 mSv 
(5 rem) of I-131 to the whole body or 500 mSv (50 rem) to the thyroid, and 
that no member of the public exceeds 1 mSv (0.1 rem) to the whole body. 
Standards and regulations have 
been established to limit the 
use of I-131 for medical 
purposes and the concentration 
of I-131 released into the 
environment. 
Table 3. Summary of Recommended Maximum Concentrations of I-131 in Specific Media and for 
Occupational Exposure 
Agency	 Media Standard 
U.S. Environmental	 Drinking water  4 Becquerels per liter 
Protection Agency	 (108 pCi/L) 
Air 100 pCi/m3 
Food and Drug Food in commerce 170 Becquerels per kilogram 
Administration (derived intervention level)* (4,600 pCi/kg) 
NRC, DOE, OSHA, Annual occupational 50 mSv (5 rem) (whole body) 
National Council on Radiation exposure limits† 
Protection and Measurement (NCRP), 500 mSv (50 rem) (thyroid) 
and International Commission on 
Radiological Protection (ICRP) 
* Foods destined for general consumption and also for infant milk and drinking water. 
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Answers to Pretest and 
Challenge Questions 
Pretest 
(a)	 The thyroid gland is the critical organ for I-131 exposure. 
Essentially all of the iodine entering the body quickly becomes 
systemic (EPA 1988), with approximately 30% depositing in the 
thyroid. 
(b)	 The main route of human internal I-131 exposure of humans is 
ingestion of contaminated fresh dairy products, eggs, and leafy 
vegetables, depending on downwind distance from the release; the 
major source of internal exposure is milk consumption. Goat's and 
sheep's milk contain approximately 10 times the concentration of 
radioiodine found in cow's milk. 
(c)	 I-131 in large amounts can produce thyroiditis. Hypothyroidism 
and thyroid cancer can result from smaller exposures of I-131 and 
its accumulation in the thyroid gland. 
(d)	 Infants and children are the groups most sensitive to I-131 
exposure. The dose to children is much higher than for adults 
because the thyroid mass in children is smaller than that for adults; 
the first week of life is an especially vulnerable period. Populations 
in the former Soviet Union exposed to much larger radiation doses 
(especially those affected by the Chernobyl nuclear release) 
showed an increased incidence of thyroid cancer for children 
younger than 15 years old at the time of the release. 
Challenge 
(1)	 The main sources of I-131 in the environment have been from 
nuclear power plant releases and nuclear weapons production and 
testing. The main sources in the United States have been the 
Nevada test site and the Hanford Nuclear Reservation. 
(2)	 Dietary intake of iodine before exposure is important because a 
relative iodine deficiency increases the thyroid uptake of I-131. 
After exposure, the most critical dietary information needed is the 
amount and type of milk and milk products consumed, their I-131 
concentrations, and the time they were consumed relative to the 
time of the release. The concentration of I-131 in goat's and sheep's 
milk is 10 times that of cow's milk. Fresh milk drunk directly on 
the farm has higher amounts of I-131 than the amount in milk that 
has been sent from the farm to the processing plant and then to a 
store. This variation in amount of I-131 is related to the short half-
life of I-131 and the decay that occurs in the time the milk is 
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processed. Although cheese and other aged-milk products tend to 
have lower amounts of I-131, it is also important to determine how 
much of these products have been consumed and what their I-131 
concentrations were when they were consumed. 
(3)	 Infants and children are the groups most sensitive to I-131 
exposure. The dose to children is much higher than the dose to 
adults because the thyroid mass in children is smaller than that of 
adults. The first week of life is an especially vulnerable period. 
Populations in the former Soviet Union exposed to much larger 
radiation doses (especially those affected by the Chernobyl nuclear 
release) showed an increased incidence of thyroid cancer for 
children younger than 15 years old at the time of the release. 
(4)	 I-131 has a strong affinity for the thyroid gland, which is the critical 
target organ for exposure. Essentially all of the iodine entering the 
body quickly becomes systemic (EPA 1988), with approximately 
30% distributing to the thyroid. 
(5)	 This patient's exposure history should include previous childhood 
head, neck, and upper mediastinum radiation exposure; previous 
residences (proximity to nuclear testing or release sites); dietary 
habits since childhood, including milk consumption and source 
(fresh vs. processed milk; whether milk was from a cow, sheep, or 
goat); source of drinking water; occupational history; and hobbies. 
Patients who consumed goat's milk contaminated with I-131 have a 
higher radiation dose of exposure than if they drank contaminated 
cow's milk from the same pasture. The patient also should be asked 
about symptoms consistent with hypothyroidism, hyperthyroidism, 
and disorders of calcium metabolism. 
(6)	 Fine needle aspiration biopsy (FNAB) is the procedure of choice 
for evaluating a palpable nodule and determining whether or not it 
is malignant. 
(7)	 Serum TSH level is a useful initial screening assay because it can 
identify patients with either thyrotoxicosis or hypothyroidism. 
Chronic autoimmune thyroiditis can present with an increased TSH 
level and a thyroid nodule. 
(8)	 Serum FT4 and T3 should be measured if TSH is abnormal. A 
serum calcitonin level should be obtained if either a medullary 
thyroid carcinoma or a multiple endocrine neoplasia type II is 
suspected. Also, because of the risk of hyperparathyroidism after 
exposure to I-131, serum calcium, phosphorus, and parathyroid 
hormone should be assessed. 
(9)	 If the nodule is found to be benign by FNAB, the patient could be 
treated with T4 in a dose sufficient to suppress serum TSH, which 
will limit glandular growth. If the nodule decreases in size, the 
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patient should be maintained on T4 indefinitely and the nodule 
monitored with ultrasound. If the nodule persists while on T4 
therapy, the patient will need a repeat FNAB. If the nodule grows 
during T4 therapy, a surgical resection is indicated. 
The patient and her husband are at higher risk for developing 
thyroid disease or thyroid cancer because they received higher 
levels of exposure to I-131 than persons who did not live near the 
Hanford Reservation during the time of the highest I-131 
emissions. The daughter is not at higher risk because she was born 
in 1963, and emissions decreased after 1962. No higher risk for any 
other disease is known. Children in the United States are screened 
at birth for thyroid function; no further thyroid tests are needed if 
the child is growing normally without other medical problems. 
Good prenatal care would be highly advised for your patient's 
daughter. However, you could reasonably reassure your patient that 
an abnormal pregnancy outcome as a result of exposure to I-131 is 
unlikely because all of the potential exposures for the patient and 
her daughter were in the past. 
If you live within 50 miles of a nuclear facility that produces or is 
capable of releasing I-131, you should work with your medical 
association, local or state public health department, emergency 
response organizations, and elected representatives to ensure that a 
stockpile of KI is available and a distribution plan is in place to 
distribute it if required. 
The perception of risk by individuals or communities can be 
affected by several factors other than how the risk is communicated. 
This includes culture, social and economic level, geographic 
location, previous experiences, and other variables inherent to the 
individual. In matters of high concern and low trust, perception 
equals reality. Peter Sandman (1993) developed the following 
framework for dealing with risk: 
“Risks that are 
natural are more readily accepted than those that are man-
made 
visible and avoidable are more readily accepted than those 
that are unseen and imposed by others 
voluntarily assumed are more acceptable than those that are 
involuntarily imposed 
familiar are more acceptable than risks that are exotic or 
unfamiliar.” 
The health care provider can encourage trust and credibility by 
getting the facts of the exposure straight, being forthcoming with 
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information that meets the needs of the individuals, coordinating 
efforts with public health agencies, and avoiding giving mixed 
messages. It is important to deal with the uncertainty; listen to and 
deal with specific concerns; convey the same information to all 
segments of the audience; and explain risk in language people 
understand, simplifying language and presentation, but not content. 
Additional Sources of 
Information 
Hanford Community Health Project (HCHP) 
HCHP is an education and outreach program for persons exposed as 
young children to past releases (between the years 1945 and 1951) of 
I-131 from the Hanford Nuclear Reservation. HCHP is sponsored by 
ATSDR and makes a variety of health information material related to 
I-131 exposure available to citizens. For more information about HCHP, 
contact 
Hanford Community Health Project or ATSDR Information Center 
1-800-207-3996 1-888-42ATSDR (1-888-422-8737) 
hanford@norcmail.uchicago.edu atsdric@cdc.gov 
www.atsdr.cdc.gov www.atsdr.cdc.gov 
National Cancer Institute 
The National Cancer Institute (NCI) has developed new educational 
materials that will help people understand their potential thyroid cancer 
risk from iodine 131 (I-131) radiation fallout from nuclear testing in the 
1950s and early 1960s. Materials include brochures, a thyroid screening 
decision aid, public service announcements, and a new interactive Web 
site that incorporates a dose calculator for assessing individual exposure. 
The NCI I-131 Web site, which includes fact sheets, PowerPoint 
presentations, a dose calculator, and many additional resources, is 
available at URL: http://www.cancer.gov/i131. You may also call NCI's 
Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) to 
receive free copies of print publications. 
Additional Sources of Information 
More information on the adverse effects of I-131 and the treatment and 
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state and local health departments, and university medical centers. For 
clinical consultation and assistance, physicians and other health care 
providers are urged to contact the following: 
Radiation Emergency Assistance Center/Training Site (REAC/TS) 
c/o Oak Ridge Institute for Science and Education 
P.O. Box 117 
Oak Ridge, TN 37831-0117 
Telephone: 865-576-3131  - ask for REACTS staff on call (M-F 8am-5pm 
EST); nights, weekends and holidays call 865-576-1005 
Web site: www.orau.gov/reacts 




Chemical Transportation Emergency Center (CHEMTREC) 
Telephone: 1-800-424-9300 (24-hour hotline)
 
Web site: www.chemtrec.org (provides a reference to available resources).
 
U.S. Department of Energy (DOE) 
Telephone: 1-800-dial-DOE (1-800-342-5363) 
Web site: www.energy.gov 
DOE regional coordinating offices should be notified for radiologic 
assistance. At the request of a patient or the attending physician, a DOE 
radiologic assistance team physician can give advice about hospitalization 
and further definitive treatment. The physician can also make available 
special DOE medical facilities for the diagnosis and treatment of radiation 
injury. DOE's geographic areas of responsibility are listed below. The 
resources of 13 federal agencies are available through DOE. 
Department of Energy Regional Offices 
Region 1 
(Connecticut, Delaware, Maine, Maryland, Massachusetts, New 
Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and 
Vermont) 
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Brookhaven Area Office; Upton, Long Island, New York, NY 11973 
Telephone: 516-345-2200. 
Region 2 
(Arkansas, Kentucky, Louisiana, Mississippi, Missouri, Puerto Rico, 
Tennessee, Virgin Islands, Virginia, and West Virginia) 
Oak Ridge Operations Office; P.O. Box E; Oak Ridge, TN 37831 
Telephone: 865-525-7885. 
Region 3 
(Alabama, Canal Zone, Florida, Georgia, North Carolina, and South 
Carolina) 
Savannah River Operations Office; P.O. Box A; Aiken, SC 29802 
Telephone: 803-824-6331, extension 3333. 
Region 4 
(Arizona, Kansas, New Mexico, Oklahoma, and Texas)
 





(Illinois, Indiana, Iowa, Michigan, Minnesota, Nebraska, North Dakota, 
Ohio, South Dakota, and Wisconsin) 
Chicago Operations Office; 9800 S Cass Avenue; Argonne, IL 60439 
Telephone: 312-972-5731 or 312-972-4800. 
Region 6 
(Colorado, Idaho, Montana, Utah, and Wyoming) 
Idaho Operations Office; P.O. Box 2108; Idaho Falls, ID 83401 
Telephone: 208-526 1515. 
Region 7 
(California, Hawaii, and Nevada) 
San Francisco Operations Office; 333 Broadway; Oakland, CA 94612 
Telephone: 510-273-4237. 
Region 8 
(Alaska, Oregon, and Washington) 
Richland Operations Office; P.O. Box 550; Richland, WA 99352 
Telephone: 509-842-7381. 
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Case Studies in Environmental Medicine: 
Radiation Exposure From Iodine 131 
Evaluation Questionnaire and Posttest, Course Number SS3059 
Course Goal: 
To increase the primary care provider’s knowledge of hazardous substances in the environment and to aid the 
evaluation of potentially exposed patients. 
Objectives: 
Describe the major sources of I-131 in the environment. 
Identify the major routes of human exposure. 
Describe the population group most at risk for health effects from past exposure to I-131 and why. 
Describe the four factors contributing to the internal dose of I-131 contamination. 
Assess a patient’s environmental or occupational exposure to I-131. 
Describe the diagnostic evaluation of a thyroid nodule in an individual exposed to I-131. 
List two important actions to take if an environmental release of I-131 occurs. 
Discuss indications for prophylactic use of potassium iodine (KI) after an I-131 exposure. 
List three sources of information one could access if there is a release of I-131. 
Tell Us About Yourself 
Please read the questions carefully. Provide answers on the answer sheet (page 55). Your credit will be 
awarded based on the type of credit you select. 
1.	 What type of continuing education credit do you wish to receive? 
**Nurses should request CNE, not CEU. See note on page 53. 
A.	 CME (for physicians) 
B.	 CME (for nonphysicians) 
C.	 CNE (continuing nursing education) 
D.	 CEU (continuing education units) 
E.	 [Not used] 
F.	 [Not used] 
G.	 [Not used] 
H.	 CHES (certified health education specialist) 
I.	 None of the above 
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E. None of the above 
3. What is your highest level of education? 
A. High school or equivalent 
B. Associate, 2-year degree 
C. Bachelor’s degree 
D. Master’s degree 
E. Doctorate 
F. Other 





E. More than 15 
5. Which of the following best describes your current occupation? 
A. Environmental health professional 
B. Epidemiologist 
C. Health educator 
D. Laboratorian 
E. Physician assistant 
F. Industrial hygienist 
G. Sanitarian 
H. Toxicologist 
I. Other patient care provider 
J. Student 
K. None of the above 
6. Which of the following best describes your current work setting? 
A. Academic (public and private) 
B. Private health care organization 
C. Public health organization 
D. Environmental health organization 
E. Nonprofit organization 
F. Other work setting 
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7. Which of the following best describes the organization in which you work? 
A. Federal government 
B. State government 
C. County government 
D. Local government 
E. Nongovernmental agency 
F. Other type of organization 
Tell Us About the Course 
8. How did you obtain this course? 
A. Downloaded or printed from Web site 
B. Shared materials with colleagues 
C. By mail from ATSDR 
D. Not applicable 
9. How did you first learn about this course? 
A. State publication (or other state-sponsored communication) 
B. MMWR 
C. ATSDR Internet site or homepage 
D. PHTN source (PHTN Web site, e-mail announcement) 
E. Colleague 
F. Other 
10. What was the most important factor in your decision to obtain this course? 
A. Content 
B. Continuing education credit 
C. Supervisor recommended 
D. Previous participation in ATSDR training 
E. Previous participation in CDC and PHTN training 
F. Ability to take the course at my convenience 
G. Other 
11. How much time did you spend completing the course, and the evaluation and posttest? 
A. 1 to 1.5 hours 
B. More than 1.5 hours but less than 2 hours 
C. 2 to 2.5 hours 
D. More than 2.5 hours but less than 3 hours 
E. 3 hours or more 
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12.	 Please rate your level of knowledge before completing this course. 
A.	 Great deal of knowledge about the content 
B.	 Fair amount of knowledge about the content 
C.	 Limited knowledge about the content 
D.	 No prior knowledge about the content 
E.	 No opinion 
13.	 Please estimate your knowledge gain after completing this course. 
A.	 Gained a great deal of knowledge about the content 
B.	 Gained a fair amount of knowledge about the content 
C.	 Gained a limited amount of knowledge about the content 
D.	 Did not gain any knowledge about the content 
E.	 No opinion 
Please use the scale below to rate your level of agreement with the following statements (questions 14–28) 
about this course. 
A.	 Agree 
B.	 No opinion 
C.	 Disagree 
D.	 Not applicable 
14.	 The objectives are relevant to the goal. 
15.	 The tables and figures are an effective learning resource. 
16.	 The content in this course was appropriate for my training needs. 
17.	 Participation in this course enhanced my professional effectiveness. 
18.	 I will recommend this course to my colleagues. 
19.	 Overall, this course enhanced my ability to understand the content. 
20.	 I am confident that I can describe the major sources of I-131 in the environment. 
21.	 I am confident I can identify the major routes of human exposure to I-131. 
22.	 I am confident I can describe the population group most at risk for health effects from past exposure 
to I-131 and tell why. 
23.	 I am confident I can describe the four factors contributing to the internal dose of I-131 
contamination. 
24.	 I am confident I can assess a patient’s environmental or occupational exposure to I-131. 
25.	 I am confident I can describe the diagnostic evaluation of a thyroid nodule in an individual exposed 
to I-131. 
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26.	 I am confident I can list two important actions to take if an environmental release of I-131 occurs. 
27.	 I am confident that I can discuss indications for prophylactic use of potassium iodine (KI) after an 
I-131 exposure. 
28.	 I am confident I can list three sources of information one could access if there is a release of I-131. 
Posttest 
If you wish to receive continuing education credit for this program, you must complete this posttest. Each 
question below contains five suggested answers, of which one or more is correct. Choose all correct answers for 
each question. 




(D)	  milk. 
(E)	 dietary products. 
30.	 What age or functional group is most sensitive to thyroid disease after I-131 exposure? 
(A)	 Pregnant women between 25 and 40 years old. 
(B)	 Elderly persons (older than 65 years old). 
(C)	 Children younger than 5 years old. 
(D) School-aged athletes who practice outdoors. 
(E)	 Women between 14 and 44 years old. 
31.	 The thyroid dose of I-131 due to milk consumption is elevated 
(A) when people drink fresh cow’s milk. 
(B)	 when people drink fresh goat’s and sheep’s milk. 
(C)	  in an area with an iodine-deficient diet. 
(D) when people eat dairy products. 
(E)	 when people are inhaling the contaminated air. 
32.	 What is the initial test for screening a patient for the noncancerous effects of I-131? 
(A) Ultrasound imaging. 
(B)	 Serum TSH level. 
(C)	 Serum antithyroglobulin antibody level. 
(D) Serum antithyroid peroxidase antibody level. 
(E)	 FNAB. 
52 
Radiation Exposure From Iodine 131 
33.	 Once a nodule has been identified, how can we determine whether it is solid, cystic, or both? 
(A) Ultrasound imaging. 
(B)	 Radionuclide scan. 
(C)	 Surgical resection. 
(D) Repeat ultrasound imaging. 
(E)	 FNAB. 
34.	 After careful examination, a thyroid nodule is found. Ultrasound imaging shows that the nodule is 
solid. What should be the next diagnostic test? 
(A) T4 suppression challenge. 
(B)	 FNAB. 
(C)	 Surgical resection. 
(D)	 Radionuclide scan. 
(E)	 Repeat ultrasound imaging. 
35.	 Ultrasound imaging reveals that a thyroid nodule is a complex cyst. What diagnostic test should be 
performed next? 
(A)	 Radionuclide scan. 
(B)	 FNAB. 
(C)	 Surgical resection. 
(D)	 Serum TSH level. 
(E)	 Repeat ultrasound imaging. 
36.	 A patient who was exposed to a significant dose of I-131 years ago has a thyroid nodule and 
undergoes FNAB. The cytology report is “nondiagnostic.” What should be recommended next to this 
patient? 
(A) T4 suppression challenge. 
(B)	 Repeat FNAB. 
(C)	 Surgical resection. 
(D)	 Radionuclide scan. 
(E)	 Follow-up ultrasound imaging. 
37.	 The results of repeated FNAB of a thyroid nodule is reported by an experienced pathologist to be 
“nondiagnostic.” What should be recommended next to this patient? 
(A) T4 suppression challenge. 
(B)	 FNAB. 
(C)	 Surgical resection. 
(D)	 Radionuclide scan. 
(E)	 Repeat ultrasound imaging. 
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38.	 Ultrasound imaging reveals that a thyroid nodule is a simple cyst. What should be the next 
diagnostic test performed? 
(A) T4 suppression challenge. 
(B)	 FNAB. 
(C)	 Surgical resection. 
(D)	 Radionuclide scan. 
(E)	 Repeat ultrasound imaging. 
39.	 What is the most efficient way of evaluating whether a thyroid nodule is malignant? 
(A) Thorough physical examination, radionuclide scan, FNAB, and surgical resection. 
(B)	 Brief history, physical examination, ultrasound imaging, and radionuclide scan. 
(C)	 Thorough history, careful physical examination, FNAB, and cytologic interpretation by experienced 
pathologist. 
(D)	 Serum TSH level, serum antithyroglobulin antibody level, and serum antithyroid peroxidase antibody 
level. 
(E)	 Serum TSH level, ultrasound imaging, and FNAB. 
40.	 The following measures are needed immediately after a nuclear release occurs: 
(A) Informing the population about the risks from exposure to I-131. 
(B)	 Treatment with KI. 
(C)	 Shutting doors and windows. 
(D)	 Forbidding fresh milk consumption. 
(E)	 Thyroid screening. 
Note to Nurses 
CDC is accredited by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. 
ANCC credit is accepted by most State Boards of Nursing. 
California nurses should write in “ANCC - Self-Study” for this course when applying for relicensure. 
A provider number is not needed. 
Iowa nurses must be granted special approval from the Iowa Board of Nursing. Call 515-281-4823 or 
e-mail marmago@bon.state.ia.us to obtain the necessary application. 
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Case Studies in Environmental Medicine: 
Remember, you can access the Radiation Exposure case studies online at 
www.atsdr.cdc.gov/HEC/CSEM/ 
and complete the evaluation From Iodine 131 questionnaire and posttest 
online at www2.cdc.gov/ 
Answer Sheet, Course Number SS3117 atsdrce. 
Instructions for submitting hard-copy answer sheet: Circle your answers. 
Online access allows you to To receive your certificate, you must answer all questions. Mail or fax your 
receive your certificate as completed answer sheet to 
soon as you complete the 
Fax:770-488-4178, ATTN: Continuing Education Coordinator 
Mail: 
Agency for Toxic Substances and Disease Registry 
ATTN: Continuing Education Coordinator 
Division of Toxicology and Environmental Medicine 
1600 Clifton Road, NE (MS F-32) 
Atlanta, GA 30333 
Be sure to fill in your name and address on the back of this form. 
1. A B C D E F G H I 21. A B C D 
2. A B C D E 22. A B C D 
3. A B C D E F 23. A B C D 
4. A B C D E 24. A B C D 
5. A B C D E F G H I J K 25. A B C D 
6. A B C D E F 26. A B C D 
7. A B C D E F 27. A B C D 
8. A B C D 28. A B C D 
9. A B C D E F 29. A B C D E 
10. A B C D E F G 30. A B C D E 
11. A B C D E 31. A B C D E 
12. A B C D E 32. A B C D E 
13. A B C D E 33. A B C D E 
14 A B C D 34. A B C D E 
15. A B C D 35. A B C D E 
16. A B C D 36. A B C D E 
17. A B C D 37. A B C D E 
18. A B C D 38. A B C D E 
19. A B C D 39. A B C D E 
20. A B C D 40. A B C D E 
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Name: E-mail (not required): 
Address: 
Zip code: 
Check here to be placed on the list 
to pilot test new case studies 







Continuing Education Coordinator 
Agency for Toxic Substances and Disease Registry 
Division of Toxicology and Environmental Medicine 
1600 Clifton Road, NE (MS F-32) 
Atlanta, GA 30333 
fold here second 
Access the case studies online at 
www.atsdr.cdc.gov/HEC/CSEM/ and 
complete the evaluation questionnaire and 
posttest online at www2a.cdc.gov/atsdrce. 
Online access allows you to receive your 
certificate as soon as you complete the 
posttest. 
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